Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis.
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Donna O
DO
Bunch
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Carmen E
CE
Mendoza
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Lydia T
LT
Aybar
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Elizabeth S
ES
Kotzen
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Kerry R
KR
Colby
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Yichun
Y
Hu
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Susan L
SL
Hogan
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Caroline J
CJ
Poulton
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
John L
JL
Schmitz
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Ronald J
RJ
Falk
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
Patrick H
PH
Nachman
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
William F
WF
Pendergraft
Department of Medicine, University of North Carolina (UNC) Kidney Center, Chapel Hill, North Carolina, USA.
JulieAnne G
JG
McGregor
D000328:Adult; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000378:metabolism*; D018956:CD5 Antigens / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D018570:Risk Assessment; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018956:CD5 Antigens; D000069283:Rituximab
Autoimmune Diseases; B cells; Disease Activity; Granulomatosis with polyangiitis; Systemic vasculitis